Literature DB >> 22661216

Induction of a broad spectrum of inflammation-related genes by Coxsackievirus B3 requires Interleukin-1 signaling.

Fabienne Rehren1, Barbara Ritter, Oliver Dittrich-Breiholz, Andreas Henke, Elena Lam, Semra Kati, Michael Kracht, Albert Heim.   

Abstract

UNLABELLED: Coxsackievirus B3 (CVB3) is a major cause of acute and chronic forms of myocarditis. Previously, direct viral injury and post-infectious autoimmune response were suspected as main pathogenetic mechanisms. However, induction of pro-inflammatory cytokines may be crucial for pathogenesis in spite of host protein shut off caused by CVB3 replication. We investigated the global expression profile of pro-inflammatory genes induced by acute and persistent (carrier state) CVB3 infection in human fibroblast cell cultures with DNA microarrays, quantitative RT-PCR and ELISA. Rapid induction of a typical spectrum of about 30 inflammation-related genes (e.g., PTGS2, CCL2, IL-1β, IL-6, IL-8, CSF2, MMP-1, MMP-3, and MMP-15) suggested an essential, autocrine role of IL-1. This hypothesis was confirmed by over-expression of IL-1RI, which resulted in a cytokine response upon CVB3 infection in HEK 293 cells otherwise refractory to CVB3-caused gene expression. Blocking IL-1 receptor type I (IL-1RI)-signaling during CVB3 infection with an IL-1 receptor antagonist (IL-1ra) as well as knockdown of IL-1RI using siRNA abrogated cytokine response in human fibroblasts. Both IL-1α and IL-1β are relevant for the induction of inflammation-related genes during CVB3 infection as shown by neutralization experiments. Paracrine effects of IL-1 on the subset of non-infected cells in carrier state infected fibroblast cultures enhanced induction of inflammation-related genes.
CONCLUSIONS: A broad spectrum of inflammatory cytokines was induced by CVB3 replication via a pathway that requires IL-1 signaling. Our results suggest that IL-1ra may be used as a therapeutic agent to limit inflammation and tissue destruction in myocarditis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661216     DOI: 10.1007/s00430-012-0245-2

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  71 in total

1.  The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense.

Authors:  L A O'Neill; C A Dinarello
Journal:  Immunol Today       Date:  2000-05

2.  Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis.

Authors:  Stephane Heymans; Matthias Pauschinger; Armando De Palma; Angela Kallwellis-Opara; Susanne Rutschow; Melissa Swinnen; Davy Vanhoutte; Fangye Gao; Raimund Torpai; Andrew H Baker; Elisabeth Padalko; Johan Neyts; Heinz-Peter Schultheiss; Frans Van de Werf; Peter Carmeliet; Yigal M Pinto
Journal:  Circulation       Date:  2006-07-31       Impact factor: 29.690

3.  Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines.

Authors:  Kol A Zarember; Paul J Godowski
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

4.  Transient induction of cytokine production in human myocardial fibroblasts by coxsackievirus B3.

Authors:  A Heim; S Zeuke; S Weiss; W Ruschewski; I M Grumbach
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

5.  Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart.

Authors:  DeLisa Fairweather; Sylvia Frisancho-Kiss; Susy A Yusung; Masheka A Barrett; Sarah E Davis; Shannon J L Gatewood; Dolores B Njoku; Noel R Rose
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

6.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

7.  Role of IL-1 and tumor necrosis factor in coxsackie virus-induced autoimmune myocarditis.

Authors:  J R Lane; D A Neumann; A Lafond-Walker; A Herskowitz; N R Rose
Journal:  J Immunol       Date:  1993-08-01       Impact factor: 5.422

8.  Tumour necrosis factor-alpha induced CD70 and interleukin-7R mRNA expression in BEAS-2B cells.

Authors:  K Wolf; C Schulz; G A J Riegger; M Pfeifer
Journal:  Eur Respir J       Date:  2002-08       Impact factor: 16.671

Review 9.  Clinical and experimental aspects of viral myocarditis.

Authors:  K Leslie; R Blay; C Haisch; A Lodge; A Weller; S Huber
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

10.  Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene.

Authors:  M J Nicklin; D E Hughes; J L Barton; J M Ure; G W Duff
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  5 in total

1.  The anti-obesity drug orlistat reveals anti-viral activity.

Authors:  Elisabeth Ammer; Sandor Nietzsche; Christian Rien; Alexander Kühnl; Theresa Mader; Regine Heller; Andreas Sauerbrei; Andreas Henke
Journal:  Med Microbiol Immunol       Date:  2015-02-14       Impact factor: 3.402

2.  Characterization of coxsackievirus B3 replication in human umbilical vein endothelial cells.

Authors:  A Kühnl; C Rien; K Spengler; N Kryeziu; A Sauerbrei; R Heller; A Henke
Journal:  Med Microbiol Immunol       Date:  2014-03-11       Impact factor: 3.402

3.  MCPIP1 inhibits coxsackievirus B3 replication by targeting viral RNA and negatively regulates virus-induced inflammation.

Authors:  Min Li; Kepeng Yan; Lin Wei; Yang Yang; Qian Qian; Wei Xu
Journal:  Med Microbiol Immunol       Date:  2017-10-17       Impact factor: 3.402

Review 4.  The Roles of Cardiac Fibroblasts and Endothelial Cells in Myocarditis.

Authors:  Yunling Xuan; Chen Chen; Zheng Wen; Dao Wen Wang
Journal:  Front Cardiovasc Med       Date:  2022-04-07

5.  Inhibition of microRNA-15 protects H9c2 cells against CVB3-induced myocardial injury by targeting NLRX1 to regulate the NLRP3 inflammasome.

Authors:  Ru Tong; Tiewen Jia; Ruijie Shi; Futang Yan
Journal:  Cell Mol Biol Lett       Date:  2020-02-19       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.